Empagliflozin and progression of kidney disease in type 2 diabetes

New England Journal of Medicine

Volumn 375, Issue 4, 2016, Pages 323-334

  Wanner, Christoph ^a   Inzucchi, Silvio E ^c   Lachin, John M ^d   Fitchett, David ^e   Von Eynatten, Maximilian ^b   Mattheus, Michaela ^b   Johansen, Odd Erik ^g   Woerle, Hans J ^b   Broedl, Uli C ^b   Zinman, Bernard ^e,f   Aizenberg, D ^h   Ulla, M ^h   Waitman, J ^h   De Loredo, L ^h   Farias J ^h   Fideleff, H ^h   Lagrutta, M ^h   Maldonado, N ^h   Colombo, H ^h   Ferre Pacora, F ^h   Wasserman, A ^h   Maffei, L ^h   Lehman, R ^h   Selvanayagam, J ^h   d'Emden M ^h   Fasching, P ^h   Paulweber, B ^h   Toplak, H ^h   Luger, A ^h   Drexel, H ^h   Prager, R ^h   Schnack, C ^h   Schernthaner, G ^h   Fliesser Gorzer E ^h   Kaser, S ^h   Scheen, A ^h   Van Gaal, L ^h   Hollanders, G ^h   Kockaerts, Y ^h   Capiau, L ^h   Chachati, A ^h   Persu, A ^h   Hermans, M ^h   Vantroyen, D ^h   Vercammen, C ^h   Van de Borne, P ^h   Benhalima, K ^h   Mathieu, C ^h   Lienart, F ^h   Mortelmans, J ^h   Strivay, M ^h   Vereecken, G ^h   Keymeulen, B ^h   Lamkanfi, F ^h   Chacra, A ^h   Eliaschewitz, F ^h   Zanella, M ^h   Faludi, A ^h   Bertolami, M ^h   Hayashida, C ^h   Nunes Salles, J ^h   Monte, O ^h   Dinato, M ^h   Manenti, E ^h   Rassi, N ^h   Halpern, A ^h   Lima Filho, M ^h   Ayoub, J ^h   Felicio, J ^h   Borges, J ^h   Gross, J ^h   Sgarbi, J ^h   Betti, R ^h   Tiburcio, A ^h   Purisch, S ^h   Schmid, H ^h   Takahashi, M ^h   Castro, M ^h   Rea, R ^h   Hissa, M ^h   Geloneze Neto, B ^h   Saraiva, J ^h   Henein, S ^h   Lochnan, H ^h   Imran, S A ^h   Clayton, D ^h   Bayly, K ^h   Berlingieri, J ^h   Boucher, P ^h   Chan, Y ^h   Gupta, M ^h   Chehayeb, R ^h   Ouellett, A ^h   Ur, E ^h   Woo, V ^h   St Amour, E ^h   Terront Lozano, M ^h   Yupanqui Lozno, H ^h   Urina, M ^h   Lopez Jaramillo, P ^h   Jaramillo, N ^h   Sanchez, G ^h   Perez G ^h   Tusek, S ^h   Mirosevic, G ^h   Goldoni, V ^h   Jurisic Erzen, D ^h   Balasko, A ^h   Balic, S ^h   Drvodelic Sunic, E ^h   Canecki Varzic, S ^h   Machkova, M ^h   Weiner, P ^h   Lastuvka, J ^h   Olsovsky, J ^h   Krarup, T ^h   Ridderstrale M ^h   Tarnow, L ^h   Saetre Lihn A ^h   Christensen, P ^h   Juhl, H ^h   Urhammer, S ^h   Lund, P ^h   Adojaan, B ^h   Jakovlev, U ^h   Lanno, R ^h   Lubi, M ^h   Marandi, T ^h   Gouet, D ^h   Courreges J ^h   Zaoui, P ^h   Choukroun, G ^h   Petit, C ^h   Formagne, L ^h   Estour, B ^h   Mabire, P ^h   Daugenet, C ^h   Lemarie, B ^h   Clavel, S ^h   Aure, P ^h   Remaud, P ^h   Halimi, J ^h   Hadjadj, S ^h   Couffinhal, T ^h   Glonti, S ^h   Metreveli, D ^h   Lominadze, Z ^h   Giorgadze, E ^h   Burtchuladze, T ^h   Javashvili, L ^h   Kurashvili, G ^h   Kurashvili, R ^h   Virsaladze, D ^h   Nadareishvili, L ^h   Khomasuridze, A ^h   Cahill, T ^h   Green, F ^h   MacRury, S ^h   Waldron, M ^h   Middleton, A ^h   McKnight, J ^h   Pearson, E ^h   Butler, M ^h   Choksi, M ^h   Caldwell, I ^h   Farmer, I ^h   Wyatt, N ^h   Patrick, J ^h   O'Brien, I ^h   Devers, M ^h   Bousboulas, S ^h   Pappas, S ^h   Piaditis, G ^h   Vryonidou, A ^h   Tentolouris, N ^h   Karamitsos, K ^h   Manes, C ^h   Benroubi, M ^h   Avramidis, I ^h   Ozaki, R ^h   Tan, K ^h   Siu, S ^h   Ip, T ^h   Tsang, C ^h   Dudas, M ^h   Nagy, K ^h   Salamon, C ^h   Gero L ^h   Patkay, J ^h   Tabak, A ^h   Tamas, G ^h   Juhasz, F ^h   Szentpeteri, I ^h   Ghaisas, N ^h   Bantwal, G ^h   Mohan, V ^h   Gupta, J ^h   Sadhu, N ^h   Kulkarni, A ^h   Garg, N ^h   Reddy, S ^h   Deshpande, N ^h   Gutlapalli, K ^h   Pillai, M ^h   Premchand, R ^h   Badgandi, M ^h   Jain, S ^h   Aravind, S ^h   Shamanna, P ^h   Pandey, A ^h   Gupta, S ^h   Pramono, B ^h   Dante Saksono, H ^h   Agung, P ^h   Djoko Wahono, S ^h   Suastika, K ^h   Tanggo, Y ^h   Juwana, Y ^h   Siswanto, B ^h   Adawi, F ^h   Efrati, S ^h   Mazen, E ^h   Bashkin, A ^h   Herskovits, T ^h   Jaffe, A ^h   Schiff, E ^h   Wainstein, J ^h   Taddei, S ^h   Aiello, A ^h   Arca, M ^h   Calabro, P ^h   Cignarelli, M ^h   Fioretto, P ^h   Marchesini Reggiani, G ^h   Gnasso, A ^h   Marchionni, N ^h   Marsilii, A ^h   Bucci, M ^h   Mezzetti, A ^h   Pozzilli, P ^h   Colivicchi, F ^h   Santini, M ^h   Moro, E ^h   Semplicini, A ^h   Toscano, V ^h   Fucili, A ^h   Monno, S ^h   Furui, K ^h   Higashiue, S ^h   Hiramatsu, N ^h   Kawamitsu, K ^h   Takenaka, T ^h   Takahashi, H ^h   Hojo, F ^h   Onishi, Y ^h   Izumino, K ^h   Okubo, M ^h   Wakida, Y ^h   Kondo, Y ^h   Hieshima, K ^h   Jinnouchi, H ^h   Suzuki, A ^h   Ito, M ^h   Park, S ^h   Kim, Y ^h   Hong, T ^h   Park, H ^h   Gwon, H ^h   Kim, H ^h   Kang, K ^h   Lee, S ^h   Jeong, M ^h   Seung, K ^h   Lim, D ^h   Rha, S ^h   Tahk, S ^h   Yang, J ^h   Yoon, J ^h   Shin, M ^h   Kim, D ^h   Jeong, J ^h   Nik Ahmad, N ^h   Mustafa, N ^h   Wan Mohamed, W ^h   Fung, Y ^h   Abdul Ghani, R ^h   Chandramouli, A ^h   Chee, K ^h   Abdul Kadir, K ^h   Ling, K ^h   Abu Hassan, M ^h   Foo, S ^h   Garcia Hernandez, P ^h   Aguilar Salinas, C ^h   Vidrio Velazquez, M ^h   Flores, F ^h   Alpizar Salazar, M ^h   Micher Escalante, D ^h   Garcia Soria, M ^h   Cardona Munoz E ^h   Storms, G ^h   Schaper, N ^h   Kooy, A ^h   Krekels, M ^h   vab Bemmel, T ^h   Verhoeven, R ^h   Mulder, H ^h   Oldenburg Ligtenberg, P ^h   Gonkel, F ^h   de Jong, A ^h   van Soest, J ^h   Viergever, P ^h   Mevissen, H ^h   Lochorn, G ^h   Zwiers, G ^h   Hoogslag, P ^h   Ronner, E ^h   Nierop, P ^h   Al Windy, N ^h   Kragten, J ^h   Dekelver, P ^h   Benatar, J ^h   Krebs, J ^h   Scott, R ^h   Heggen, E ^h   Berz, A ^h   Fossum, C ^h   Hurtig, U ^h   Langslet, G ^h   Baranowski, M ^h   Sparby, J ^h   Karlsson, T ^h   Delgado Torres, C ^h   Rodriguez Escudero, A ^h   Lisson, R ^h   Allemant Maldonado, A ^h   Gallardo Rojas, W ^h   Gonzales Bravo, L ^h   Lema Osores, J ^h   Farfan, J ^h   Zapata, L ^h   Godoy Junchaya, J ^h   Roldan Concha, Y ^h   Urquiaga Calderon, J ^h   Sy, R ^h   Tan, G ^h   Aquitania, G ^h   De Los Santos, G ^h   Panelo, A ^h   Roderos, O ^h   Rosales, R ^h   Toledo, R ^h   Liwag, A ^h   Ramoncito, H ^h   Skokowska, E ^h   Krzyzagorska, E ^h   Ogorek, M ^h   Wojnowski, L ^h   Spyra, J ^h   Konieczny, M ^h   Piesiewicz, W ^h   Kus, W ^h   Ocicka Kozakiewicz, A ^h   Orlowska Kunikowska, E ^h   Zmuda, W ^h   Duarte, S ^h   Leitao A ^h   Monteiro, P ^h   Rita, H ^h   Salgado, V ^h   Pinto, L ^h   Queiros J ^h   Teixeira, J ^h   Rogado, C ^h   Duarte, R ^h   Sobral do Rosario F ^h   Silva, A ^h   Andrade, L ^h   Velez, M ^h   Brazao M ^h   Istratoaie, O ^h   Lichiardopol, R ^h   Catrinoiu, D ^h   Militaru, C ^h   Zetu, C ^h   Barbonta, D ^h   Cosma, D ^h   Crisan, C ^h   Pop, L ^h   Esip, V ^h   Arutyunov, G ^h   Boyarkin, M ^h   Agafyina, A ^h   Vorokhobina, N ^h   Petunina, N ^h   Libov, I ^h   Zalevskaya, A ^h   Nikolaev, K Yu ^h   Barbarash, O ^h   Potemkin, V ^h   Bystrova, A ^h   Krasilnikova, E ^h   Barbarich, V ^h   Chumakova, G ^h   Tarasov, N ^h   Meleshkevich, T ^h   Zateyshchikov, D ^h   Lantseva, O ^h   Belenkiy, D ^h   Obrezan, A ^h   Rossolko, L ^h   Fillipova, E ^h   Yakhontova, P ^h   Khokhlov, A ^h   Tan, R ^h   Sum, C ^h   Chang, H ^h   Distiller, L ^h   Pretorius, M ^h   Nortje, H ^h   Mitha, E ^h   Burgess, L ^h   Blignaut, S ^h   Venter, T ^h   Moodley, R ^h   Lombaard, J ^h   Govind, U ^h   Naidoo, V ^h   Mookadam, M ^h   Engelbrecht, J ^h   Omar, M ^h   Jurgens, J ^h   Podgorski, G ^h   Vawda, H ^h   Naidoo, D ^h   Emanuel, S ^h   Roodt, A ^h   Amod, A ^h   Van Zyl, L ^h   Segura, J ^h   Brito, M ^h   Fernandez Cruz, A ^h   Artola, S ^h   Iglesias, R ^h   Toural, E ^h   Garcia Ortiz, L ^h   Saban, J ^h   Mesa, J ^h   Vidal, J ^h   Linares, J ^h   del Canizo F ^h   Rigla, M ^h   Suarez, C ^h   Llorente, I ^h   Moreno, B ^h   Antoli, A ^h   Gomez Peralta, F ^h   Iglesias, M ^h   Pereg, V ^h   de Teresa, L ^h   Camafort, M ^h   Trescoli, C ^h   Satarasinghe, R ^h   Somasundaram, N ^h   Siyambalapitiya, S ^h   Antonypillai, C ^h   Bulugahapitiya, D ^h   Medagama, U ^h   Huang, C ^h   Lu, Y ^h   Hwang, J ^h   Chiang, C ^h   Wen, M ^h   Chen, J ^h   Lai, W ^h   Chang, K ^h   Wang, J ^h   Yeh, H ^h   Kriangsak, P ^h   Deerochanawong, C ^h   Suwanwalaikorn, S ^h   Mangklabruks, A ^h   Kaewsuwanna, P ^h   Piyayotai, D ^h   Iabluchanskyi, M ^h   Samoylov, O ^h   Godlevska, O ^h   Kovalyova, O ^h   Voloshyna, O ^h   Tseluyko, V ^h   Zotov, S ^h   Vykhovanyuk, I ^h   Dulgeroff, A ^h   Mayfield, R ^h   Zaniewski Singh, M ^h   Ullal, J ^h   Aloi, J ^h   De La Rosa, R ^h   Mosely, J ^h   Wittmer, B ^h   Aronoff, S ^h   Rosenfeld, J ^h   Seidner, M ^h   Warren, M ^h   Fishman, N ^h   Weiss, R ^h   Arif, A ^h   Sandberg, M ^h   Lewis, D ^h   Ball, E ^h   Graf, R ^h   Breton, C ^h   Tamayo, R ^h   Richards, R ^h   Cefalu, W ^h   Uwaifo, G ^h   Zayour, D ^h   Hoffman, J ^h   Fitz Patrick, D ^h   Khan, B ^h   Blaze, K ^h   Bressler, P ^h   Halpern, S ^h   Chappell, D ^h   Bergenstal, R ^h   Cuddihy, R ^h   Matfin, G ^h   Freedman, Z ^h   Gonzalez Campoy, J ^h   Lerman, S ^h   Rendell, M ^h   Sitar, S ^h   Reeves, M ^h   Howard, T ^h   Soufer, J ^h   Miranda Palma, B ^h   Laliotis, A ^h   Shomali, M ^h   Teltser, M ^h   Hurley, D ^h   Morawski, E ^h   Cherlin, R ^h   Houchin, V ^h   Welch, M ^h   Goytia Leos, D ^h   Syed, M ^h   Kowaloff, E ^h   Weinrauch, L ^h   Peniston, J ^h   Brockmyre, A ^h   First, B ^h   Feld, L ^h   Huffman, D ^h   Nassim, O ^h   Gottschlich, G ^h   Patel, A ^h   Knopke, C ^h   Hernandez, M ^h   Diaz, J ^h   Giugliano, G ^h   Nicasio, J ^h   Eagerton, D ^h   Huntley, R ^h   Reed, J ^h   Magee, M ^h   Hippert, R ^h   Sofley, C ^h   Alzohaili, O ^h   Levins, P ^h   Anspach, R ^h   Shah, S ^h   Brusco, O ^h   Naidu, J ^h   Lindenbaum, J ^h   Jacks, R ^h   Hammond, G ^h   Arena, C ^h   Saxman, K ^h   Mach, M ^h   Kerstein, H ^h   Kereiakes, D ^h   Wahlen, J ^h   Wehmeier, K ^h   Chaykin, L ^h   Rothman, J ^h   Fogelfeld, L ^h   Stroger, J ^h   Bittar, N ^h   Rosenstock, J ^h   Kayne, D ^h   Navarro, J ^h   Colfer, H ^h   Mokshagundam, S ^h   Shandilya, L ^h   Connery, L ^h   Wysham, C ^h   Dela Llana, A ^h   Jardula, M ^h   MacAdams, M ^h   Flippo, G ^h   Heurich, E ^h   Curtis, C ^h   Sanders, D ^h   Rawls, R ^h   Velazquez, F ^h   Osea, E ^h   Mahood, K ^h   Feldman, G ^h   Eder, F ^h   Riley, E ^h   Jain, M ^h   Fowler, W ^h   Shepard, M ^h   Schear, M ^h   Barker, B ^h   Strout, C ^h   Obiekwe, O ^h   Shanik, M ^h   Green, C ^h   Blakney, E ^h   Roberson, K ^h   Bretton, E ^h   Pish, R ^h   Kaveh, K ^h   Maynard, B ^h   Barager, W ^h   Soldyshev, R ^h   Austin, B ^h   Parmar, P ^h   Simpson, R ^h   Chauhan, A ^h   Kasper, J ^h   Burr, R ^h   Patel, N ^h   Mariano, H ^h   Pluto, T ^h   Bratcher, C ^h   Juarez, M ^h   Levinson, L ^h   Awad, A ^h   Longshaw, K ^h   Hoffman, K ^h   Richwine, R ^h   Molter, D ^h   Boscia, J ^h   Kowalyk, S ^h   Lemis, P ^h   Liss, J ^h   Orr, R ^h   Riser, J ^h   Wood, J ^h   Ubani, A ^h   Paine, W ^h   Hassani, F ^h   Miranda, F ^h   Hansen, V ^h   Farris, N ^h   Bowden, R ^h   Ajani, D ^h   Maw, K ^h   Andersen, J ^h   Bergman, B ^h   Dunmyer, S ^h   Brandon, D ^h   Anderson, M ^h   Bononi, P ^h   Prawer, J ^h   Seidman, B ^h   Cruz, H ^h   Wilks, K ^h   DiSanto, L ^h   Buynak, R ^h   Christensen, T ^h   Denker, P ^h   Koppel, W ^h   Stedman, M ^h   Lewy Alterbaum, L ^h   Karim, S ^h   Shapiro, J ^h   Gardner, T ^h   Oskin, T ^h   Gabra, N ^h   Malano, J ^h   Welty, F K ^h   Parhofer, K G ^h   Pedersen, T R ^h   Lees, K R ^h   Clayton, T ^h   Pocock, S ^h   Palmer, M ^h   Clemmensen, P ^h   Grande, P ^h   Pehrson, S ^h   Januzzi, J ^h   Wood, M J ^h   Petrie, M ^h   Sairanen, T ^h   Tatlisumak, T ^h   Soinne, L ^h   Kase, C ^h   Turan, T ^h   Watkins, P ^h   Lewis, J ^h   Freston, J ^h   Schenker, S ^h   Heist, R ^h   Lee, R J ^h   Natale, R B ^h   Sullivan, R J ^h   Buchbinder, E I ^h   Chodak, G ^h   Schumacher, M ^h   Schmoor, C ^h   Hieke, S ^h   more..

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g Boehringer Ingelheim Norway KS   (Norway)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EMPAGLIFLOZIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMINURIA; ARTICLE; BODY SURFACE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DISEASE COURSE; DRUG SAFETY; FEMALE; FRACTURE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LONG TERM CARE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PYELONEPHRITIS; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; UROSEPSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; KIDNEY; MICROVASCULATURE; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VASCULARIZATION;

AGED; ALBUMINURIA; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MICROVESSELS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84979895487     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1515920     Document Type: Article

References (39)

1. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
2. de Boer IH, Rue TC, Hall YN, Hea-gerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9.
3. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-8.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
5. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes melli-tus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012; 172: 761-9.
6. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
7. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83: 517-23.
8. Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:1392-406.
9. Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 2014;10:77-87.
10. Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 2015; 87: 20-30.
11. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:613-21.
12. Häring HU, Merker L, Seewaldt-Becker E, et al. Empaglif lozin as add-on to met-formin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36:3396-404.
13. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to met-formin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9.
14. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pio-glitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-58.
15. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sita-gliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-19.
16. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815-23.
17. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empa-gliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48.
18. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-8.
19. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-84.
20. Skrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemody-namic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperf iltrat ion. Diabetologia 2014; 57: 2599-602.
21. Cherney DZ, Perkins BA, Soleyman-lou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mel-litus. Circulation 2014;129:587-97.
22. Škrtić M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hyper-tens 2015;24:96-103.
23. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
24. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014;13:102.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-70.
26. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
27. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
28. Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015;17:1180-93.
29. Cherney DZ, Perkins BA, Soleyman-lou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Dia-betol 2014;13:28.
30. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306:F194-204.
31. Cherney DZ, Perkins BA, Soleyman-lou N, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 2014;86:1057-8.
32. Jordan J, Tank J, Heusser K, et al. Em-pagliflozin has no discernable effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight. Diabetes 2014;63:Suppl 1:A265 (poster).
33. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angio-tensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
34. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
35. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
36. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20.
37. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angio-tensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-87.
38. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104:1985-91.
39. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glo-merular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011;80:282-7.